Agentix
$0.03
4
+$0+6.31% Friday 20:41
Statistics
Day High
0.03
Day Low
0.03
52W High
0.2
52W Low
0.03
Volume
300
Avg. Volume
316
Mkt Cap
7.82M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Earnings
14NovConfirmed
Q4 2020
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.05
-0.03
-0.02
-0
Expected EPS
N/A
Actual EPS
-0.01
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AGTX. It's not an investment recommendation.
About
Producer Manufacturing
Metal Fabrication
Manufacturing
Plastics Material and Resin Manufacturing
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
Show more...
CEO
Country
US
ISIN
US00848A1034